[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Asthma - Pipeline Review, H2 2020

October 2020 | 811 pages | ID: A8EEC930D7CEN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Asthma - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Asthma - Pipeline Review, H2 2020, provides an overview of the Asthma (Respiratory) pipeline landscape.
Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Asthma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Asthma (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Asthma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 16, 42, 36, 4, 126, 31 and 10 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 30 and 9 molecules, respectively.
Asthma (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Asthma (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Asthma (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Asthma (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Asthma (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Asthma (Respiratory)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Asthma (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Asthma (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Asthma - Overview
Asthma - Therapeutics Development
Asthma - Therapeutics Assessment
Asthma - Companies Involved in Therapeutics Development
Asthma - Drug Profiles
Asthma - Dormant Projects
Asthma - Discontinued Products
Asthma - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Asthma, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Asthma - Pipeline by 2A Pharma AB, H2 2020
Asthma - Pipeline by 3SBio Inc, H2 2020
Asthma - Pipeline by 4D Pharma Plc, H2 2020
Asthma - Pipeline by AB Science SA, H2 2020
Asthma - Pipeline by AbbVie Inc, H2 2020
Asthma - Pipeline by Abeome Corp, H2 2020
Asthma - Pipeline by Adamis Pharmaceuticals Corp, H2 2020
Asthma - Pipeline by Adare Pharma Solutions, H2 2020
Asthma - Pipeline by Advagene Biopharma Co Ltd, H2 2020
Asthma - Pipeline by Aerami Therapeutics, H2 2020
Asthma - Pipeline by Airbase Breathing Co LLC, H2 2020
Asthma - Pipeline by Akeso Inc, H2 2020
Asthma - Dormant Projects, H2 2020
Asthma - Discontinued Products, H2 2020

LIST OF FIGURES

Number of Products under Development for Asthma, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020


More Publications